Cite
Chiang AS, Loblaw DA, Jethava V, et al. Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancer. Can Urol Assoc J. 2013;7(11):450-3doi: 10.5489/cuaj.262.
Chiang, A. S., Loblaw, D. A., Jethava, V., Sethukavalan, P., Zhang, L., Vesprini, D., Mamedov, A., Nam, R., & Klotz, L. (2013). Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancer. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 7(11), 450-3. https://doi.org/10.5489/cuaj.262
Chiang, Andrew S, et al. "Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancer." Canadian Urological Association journal = Journal de l'Association des urologues du Canada vol. 7,11 (2013): 450-3. doi: https://doi.org/10.5489/cuaj.262
Chiang AS, Loblaw DA, Jethava V, Sethukavalan P, Zhang L, Vesprini D, Mamedov A, Nam R, Klotz L. Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancer. Can Urol Assoc J. 2013 Nov-Dec;7(11):450-3. doi: 10.5489/cuaj.262. PMID: 24381668; PMCID: PMC3876449.
Copy
Download .nbib